Phase III Pembrolizumab Trial in Head and Neck Cancer: AACR 2025
Patients with newly diagnosed, locally advanced head and neck squamous cell carcinoma (HNSCC) may soon benefit from a major shift in treatment strategy, as phase III trial data show that perioperative pembrolizumab significantly improves outcomes when added to standard care.